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Our previous biochemical studies of HIV-1 and MuLV virions isolated and identified mature Gag products, HIV-1 p6Gag and
MuLV p12Gag, that were conjugated to a single ubiquitin. To study the importance of the monoubiquitination of Gag, a series
of lysine to arginine mutants were constructed that eliminated ubiquitination at one or both of the lysines in HIV-1NL4-3 p6
Gag
and both lysines in Moloney MuLV p12Gag. HPLC and immunoblot analysis of the HIV-1 mutants demonstrated that either of
the lysines in p6Gag, K27 or K33, could be monoubiquitinated. However, infectivity assays showed that monoubiquitination of
HIV-1 p6Gag or MuLV p12Gag is not required for viral replication in vitro. Pulse-chase radiolabeling of HIV-1-producing cells
revealed that monoubiquitination of p6Gag does not affect the short-term release of virus from the cell, the maturation of
Pr55Gag, or the sensitivity of these processes to proteasome inhibitors. Experiments with protease-deficient HIV-1 showed
that Pr55Gag can be monoubiquitinated, suggesting that p6Gag is first modified as a domain within Gag. Examination of the
proteins inside an HIV-1 mutant found that free ubiquitin was incorporated into the virions in the absence of the lysines in
p6Gag, showing that the ubiquitin inside the virus is not initially brought in as a p6Gag conjugate. Although our results establish
Gag Gagthat monoubiquitination of p6 and p12 is not required for viral replication in vitro, this modification may be a by-product
of interactions between Gag and cellular proteins during assembly and budding. © 2000 Academic Press
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CINTRODUCTION
Retroviral Gag, the primary structural protein of the
virion, assembles at the plasma membrane of the host
cell and then buds from the cell surface (for review see
Kra¨usslich and Welker, 1996; Swanstrom and Wills, 1997;
Vogt, 1997). It is the only viral protein strictly required for
particle assembly and budding, although genomic RNA,
the Envelope protein complex, and the Gag-Pol precur-
sor protein are required to produce an infectious virion.
After virus release, the Gag polyprotein is cleaved into its
mature proteins by the retroviral protease, which in turn,
produces the structural rearrangement of the virion from
a noninfectious, immature form into an infectious, mature
form. The Gag polyprotein is organized into functional
domains that provide for viral RNA recognition and bind-
ing, membrane association, virion formation, and effi-
cient particle release from the plasma membrane (Kra¨us-
slich and Welker, 1996; Swanstrom and Wills, 1997; Vogt,
1997). Gag polyproteins in all retroviruses (except spu-
maviruses) are processed to yield several mature pro-
teins, MA, CA, and NC, that provide different functions
during infection. In addition to these common proteins,
the Gag proteins of retroviruses usually contain other
mature proteins that vary among the retroviruses. In
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111several cases, some of these proteins contain a late (L)
domain, which is required for efficient budding: muta-
tions or deletions of these sequences produce a virus
that forms a bud that releases poorly from the cell sur-
face (Gottlinger et al., 1991; Huang et al., 1995; Parent et
l., 1995; Puffer et al., 1997). The L domain in HIV-1, PTAP,
s found in the p6Gag protein which is present at the
-terminus of HIV-1 Gag (Pr55Gag), whereas the L domain
for MuLV, PPPY, is in the p12Gag protein, located between
MA and CA in MuLV Gag (Pr65Gag) (Huang et al., 1995;
Yuan et al., 2000). It is currently not known how these L
domains function within the cell to assist viral release.
Previously, we found that approximately 2% of the
mature p6Gag within HIV-1 and 5% of the mature p12Gag in
murine leukemia virus (MuLV) were conjugated to a
single ubiquitin (i.e., monoubiquitinated) in their respec-
tive virions (Ott et al., 1998). Although monoubiquitination
has been shown to be a signal for endocytosis (Shih et
al., 2000), this modification might have other functions
that are currently unknown. Even though polyubiquitina-
tion (i.e., the addition of polymeric [more than four mono-
mers] ubiquitin chains) is a well-known signal for protein
degradation by the proteasome, monoubiquitination
does not appear to be involved in protein turnover (Finley
and Chau, 1991; Hershko and Ciechanover, 1998; Hoch-
strasser, 1996; Laney and Hochstrasser, 1999; Thrower
et al., 2000). Ubiquitin is specifically attached to the
target protein by an isopeptide linkage between the
C-terminal carboxyl group of ubiquitin and the e-amino
0042-6822/00 $35.00
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112 OTT ET AL.group of lysine that is performed by either an E2 or E3
enzyme that recognizes its target protein. Although the
total number of proteins is not known, it is thought that
there are more than 20 E2 and E3 enzymes in mammalian
cells (Scheffner et al., 1998).
We tested the importance of the ubiquitination of HIV-
1NL4-3 p6
Gag and MuLV p12Gag, using site-directed mu-
agenesis that altered the potential sites of modification.
or HIV-1, our results indicate that p6Gag is monoubiquiti-
nated within Pr55Gag and that this p6Gag modification is
ot required for ubiquitin incorporation into the virion.
nalysis of these mutants showed that the ubiquitination
f either p6Gag in HIV-1 or p12Gag in MuLV is not crucial for
iral assembly, budding, or replication.
RESULTS
The p6Gag protein of HIV-1NL4-3 has two lysines at resi-
dues 27 and 33 that are conserved among nearly all
isolates of HIV-1 (Myers et al., 1995). To test the impor-
tance of p6Gag monoubiquitination, these two residues
ere altered in the pNL4-3 infectious molecular clone,
ither singly or in combination, from lysine to arginine, a
onservative change to a basic amino acid that lacks the
e-amino group required for an isopeptide linkage with
ubiquitin. These mutations were introduced into Gag
without altering the Pol reading frame, which overlaps
this region (i.e., the mutations in p6Gag changed only the
edundant bases in the 21 frameshifted pol codons).
hese mutant constructs, containing lysine-to-arginine
ubstitutions at residue 27 (K27R) or residue 33 (K33R) or
t both residues (K27R-K33R) (Fig. 1), were used to pro-
uce virions by transfecting 293T cells. All of the mutants
onsistently produced near wild-type levels of virions as
easured by the release of reverse transcriptase into
he supernatant (data not shown), indicating no gross
ssembly or budding defect.
rotein analysis of HIV-1 mutants
Gag
FIG. 1. Sequences of viral mutants. The mutations made in HIV-1
6Gag and MuLV p12Gag are presented in single amino acid code un-
derneath their respective wild-type sequences. Amino acids are num-
bered above the sequences and the late domain for each virus is
denoted by underlining.Since the mutations introduced in p6 should elimi-
ate ubiquitination, the proteins in the virions, after su-rose density centrifugation, were examined by immuno-
lot analysis using p6Gag antiserum. The results showed
that all of the virion samples contained an 8-kDa band
corresponding to p6Gag (Fig. 2). This antiserum also de-
tected a 55-kDa band that corresponds to Pr55Gag in the
virion preparations. The differences in the p6Gag signals
and mobilities among the virion samples are the result of
poor binding efficiency of mature p6Gag to the blotting
embrane and the altered electrophoretic and blotting
haracteristics of the various mutant proteins (unpub-
ished data as discussed in Ott et al., 1999). In the
ild-type, K27R, and K33R samples, there also was a
7-kDa band, which is consistent with the size previously
bserved for the ubiquitin-p6Gag conjugate (Ott et al.,
998) (Fig. 2). However, this band was not detected in the
ample from the K27R-K33R p6Gag double mutant, which
has no lysines for ubiquitin attachment, suggesting that
these virions did not contain the p6Gag-ubiquitin conju-
gate as expected. In addition to the bands described
above, there are less intense bands in the p6Gag immu-
noblot that have not been characterized (Fig. 2). Ubiquitin
FIG. 2. Analysis of wild-type and mutant virions. Immunoblots of virus
samples produced by transfection. One-tenth of each preparation (ap-
proximately 600,000 cpm of reverse transcriptase activity) was ana-
lyzed. Each sample is labeled above its respective lane and the anti-
serum or antibody used is indicated above each blot. A preparation
from a sheared salmon sperm DNA (sssDNA) transfection is included
as a negative control. Molecular weights, calculated by relative mobility
with a standard, are indicated at left and our protein assignments are
presented at right.
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113UBIQUITINATION OF HIV-1 AND MuLV Gagimmunoblots of the relatively limited amounts of virions
produced by transfection could not clearly detect the
p6Gag–ubiquitin conjugate, likely because of the small
mount of this protein in virions, the potential presence
f diubiquitin, and the sensitivity of the antibody (Ott et
l., 1998).
A p24CA immunoblot of the virions showed that p24CA,
Pr55Gag, and their processing intermediates were present
t nearly equal amounts in both the wild-type and the
utant samples. These results show that the processing
f Gag was normal in all of the mutants (Fig. 2). It was
ecently shown that mutations in the N-terminus of p6Gag
can cause a loss of mature Pol proteins in the virions
(Dettenhofer and Yu, 1999). Immunoblots for reverse tran-
scriptase and protease detected nearly equal amounts of
these mature proteins in all the samples (Fig. 2). There-
fore, the incorporation of Pol proteins is unaffected by
any of these p6Gag mutations. Taken together, these re-
ults confirm that these mutants efficiently bud and that
hey process Gag and Gag-Pol.
The above-mentioned immunoblotting results suggest
hat the single lysine-to-arginine mutants can be ubiqui-
inated, while the double mutant is not conjugated to
biquitin. However, the inability to demonstrate a co-
eacting band in ubiquitin and p6Gag immunoblots of
whole virus led us to confirm and better characterize
these results by employing micro-reversed-phase HPLC.
This technique can separate and isolate the proteins
from the relatively small amounts of virions produced by
transfection, so that the p6Gag–ubiquitin conjugates can
e more clearly analyzed (Ott et al., 1999). Wild-type,
K27R, K33R, and K27R-K33R virion preparations, pro-
duced by transfection and isolated by sucrose density
centrifugation, were analyzed by HPLC under conditions
that allowed the isolation of the p6Gag–ubiquitin conju-
ates from the fractions that contained intact p6Gag and
ubiquitin (Fig. 3). Comparison of all of the HPLC chro-
matograms showed that each sample contained essen-
tially equal amounts of all of the Gag cleavage products
(the chromatogram of the wild-type, NL4-3 virus is shown
in Fig. 3). Immunoblots of HPLC fractions showed that all
of the samples analyzed contained p6Gag and ubiquitin in
raction 32. Additionally, only the wild-type, K27R, and
33R virion samples produced bands in fractions 34 and
5 that reacted with both ubiquitin antibody and p6Gag
antiserum, indicating that they contained p6Gag–ubiquitin
conjugates (Fig. 3).
All of these virions contained a 17-kDa species in
fraction 34 that coreacted with both ubiquitin antibody
and p6Gag antiserum, confirming the presence of a mo-
oubiquitinated p6Gag complex that was previously found
n HIV-1 virions (Ott et al., 1998). In addition to this band,
17-kDa species was detected in fraction 32 that reacts
ith p6Gag and not ubiquitin, indicating that it is not a
Gagp6 –ubiquitin conjugate. The identity of this band is
nknown; however, it does not react with SP2 (p1Gag) orp7NC antiserum and thus is not the p15 (i.e., p7NC–SP2–
p6Gag) partial cleavage product (data not shown). An
dditional 24-kDa band that coreacted with both ubiq-
itin and p6Gag blots was present in fraction 35 of the
FIG. 3. HPLC and immunoblot analysis of virions. A representative
HPLC analysis (wild-type) is shown with the area studied by immuno-
blot expanded and presented below the chromatogram. Blotting results
of the indicated HPLC fractions for each virus are presented. The virus
sample is indicated at left while the fractions analyzed are labeled
above each blot. The antibody or antiserum used for each blot is
indicated above the lanes.wild-type and K27R samples and in fraction 34 of the
K33R samples, indicating that this form is a diubiquiti-
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114 OTT ET AL.nated p6Gag conjugate. These 24-kDa bands did not react
with p1Gag or p7NC antiserum, showing that it is not a
monoubiquitinated form of the p15Gag partial cleavage
product (data not shown). Taken together, these results
show that either lysine in p6Gag can be mono- or diubiq-
uitinated. Immunoblotting of several of the adjacent frac-
tions for other ubiquitinated p6Gag species failed to detect
any coreacting bands, though the existence of an even
smaller amount of ubiquitinated p6Gag being present in
the virions cannot be ruled out. Other bands in the blots
migrated higher than did ubiquitin and p6Gag bands but
did not coreact in both immunoblots and thus are not
p6Gag–ubiquitin conjugates. The higher migrating ubiq-
itin bands present in the fractions could be ubiquiti-
ated cellular proteins, whereas the other p6Gag bands
ould be Gag-processing products or modified forms of
6Gag that have yet to be identified.
In contrast to the results from the wild-type and two
ingle-mutant samples, immunoblotting of HPLC frac-
ions from the K27R-K33R double-mutant sample failed to
etect any ubiquitin–p6Gag conjugates (Fig. 3). However,
blots of an equal percentage of fraction 32 readily de-
tected both p6Gag and ubiquitin. These results confirm the
immunoblot data that the K27R-K33R mutations elimi-
nated the ubiquitination of p6Gag as expected.
Kinetics of K27R-K33R budding and Pr55Gag
processing
Since p6Gag contains the L domain, required for effi-
cient Gag processing and viral budding, we examined
the short-term kinetics of Gag processing and virion
release of the K27R-K33R mutant by pulse-chase exper-
iments to determine whether these nearby mutations
(Fig. 1) would affect viral budding. Pr55Gag produced in
HeLa cells, transfected with either wild-type or K27R-
K33R DNAs, was metabolically labeled for 30 min with a
[35S]methionine pulse, followed by a nonradioactive me-
thionine chase. To follow the fate of the newly produced
Pr55Gag proteins, the amount of labeled Gag proteins
(Pr55Gag and its cleavage products) present in samples of
virions pelleted from cell culture supernatants, clarified
cell culture supernatants (free protein), or cell lysates
harvested during the chase period was detected by im-
munoprecipitation with AIDS patient serum, SDS–PAGE,
and phosphorimager analysis. Representative results
from one of the three independent experiments are
shown. The relative amounts of Pr55Gag and processed
A (i.e., p24CA or p24CA–SP1) detected over the chase
period revealed that the K27R-K33R mutant virions were
released as efficiently as those of wild-type (Figs. 4A and
4B), especially during the 2-h chase period. However,
image quantitation of three pulse-chase experiments
showed that the cells transfected with the mutant pro-
duced 1.3-fold more Gag from the cell than did the wild-
type particles at the end of the 8-h chase (Fig. 4C and
a
odata not shown). Comparison of the amounts of Pr55Gag
and its conversion into CA in the pulse-chase experi-
ments over time did not show any difference in either the
stability or the processing of the mutant and wild-type
Gag inside either cells or virions (Fig. 4A and data not
shown). Taken together, these results show no large
differences in short-term viral release between the K27R-
K33R mutant and wild-type.
In a separate study, we found that treatment of HIV-1-
producing cells with proteasome inhibitors (compounds
that inhibit the 26S proteasome complex that degrades
polyubiquitinated proteins) (Lee and Goldberg, 1998) sig-
nificantly reduced viral release and processing of Pr55Gag
and eliminated the conjugation of ubiquitin to p6Gag
(Schubert et al., in press). Since it is possible that the
inhibition of p6Gag ubiquitination could be responsible for
hese proteasome inhibitor effects, we used pulse-chase
xperiments to determine the kinetics of virus release
rom cells expressing K27R-K33R and wild-type virions in
he presence of the proteasome inhibitors N-carboben-
oxyl-L-leucinyl-L-leucinyl-leucinal (zLLL) and lactacystin
LC). To inhibit proteasome function we used conditions
hat were sufficient to completely block 26S proteasome
unction without the toxic effects that can be produced by
hese inhibitors (Schubert et al., 1998, 2000, in press): 10
mM z-LLL and LC were added to the virus-expressing
cells 30 min prior to pulse-labeling with [35S]methionine
nd were present throughout the entire experiment. Un-
er these conditions, similar amounts of radiolabeled
iral proteins were detected in the parallel treated and
ntreated cultures (Fig. 4A), demonstrating that this short
retreatment with proteasome inhibitors did not signifi-
antly affect the level of protein synthesis. Also, cells
emained intact during treatment, as cell viability (mea-
ured by trypan blue exclusion) was the same for both
reated and untreated cultures (data not shown) and
imilar amounts of nonparticulate Gag were present in
he clarified cell culture supernatants (Fig. 4C). Together,
hese results show that inhibitor treatment did not cause
onspecific release of viral proteins by cell leakage and
id not affect protein synthesis during these experi-
ents.
Similar to our previous results (Schubert et al., in
ress), treatment of cells expressing wild-type HIV-1 with
roteasome inhibitors significantly reduced the amount
f virus released during the 8-h chase period compared
o the results from the untreated cells (Figs. 4A and 4B).
n addition to delayed viral release, the processing of
r55Gag was correspondingly reduced in the treated cul-
ure (Fig. 4A). The results for the cells expressing the
27R-K33R mutant were similar to those expressing wild-
ype virus. Therefore, the sensitivity of viral processing
nd release to proteasome inhibitors is not dependent
n the ubiquitination of p6Gag.
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115UBIQUITINATION OF HIV-1 AND MuLV GagInfectivity of p6Gag mutants
The infectivity of the mutants was measured by a Tat-
omplementation lacz indicator cell assay (HCLZ; an assay
imilar to the MAGI assay) (Kimpton and Emerman, 1992)
hat detects infected cells by blue color staining with 5-bro-
o-4-chloro-3-inolyl-b-D-galactoside (Gorelick et al., 1990).
The results indicated that all of these mutants produced
titers similar to those of the wild-type samples (represen-
tative data are shown in Table 1). Consistent with this result,
examination of the rate of viral spread on H9 cells by the
K27R-K33R mutant and wild-type viruses produced similar
results; all of the viruses replicated similarly on these cells
(Fig. 5). These results show that the viral production and
infectivity were not affected by the mutations.
Ubiquitin modification of Pr55Gag
Gag
FIG. 4. Release of virions from cells. (A) Phosphorimages of SDS–PA
presented for cell and viral lysates from transfected HeLa cells that w
0 mM lactacystin). The respective DNAs used to transfect the cells a
denoted above each image. The time during the chase period (0, 0.5, 1
(B) Graphs of the results of the pulse-chase experiments, as quantitate
the cell as particles (pelletable Gag) versus the total amount of Gag
associated with virions from cells (nonpelletable, free protein) is presen
versus the total amount of Gag both inside and outside the cell versuSince HIV-1 buds primarily as Pr55 , ubiquitin is most
ikely conjugated to the p6Gag region of the polyproteinefore or during assembly rather than to the mature
6Gag. To determine whether the p6Gag domain of Pr55Gag
is ubiquitinated, mutants were constructed that con-
tained either wild-type or K27R-K33R p6Gag sequences in
combination with a protease-inactivating mutation (an
arginine-to-glycine change in protease residue 57) to
TABLE 1
Infectivity of p6Gag Mutants
Virus HCLZ titera
sssDNAb 4
NL4-3 1.9 3 106
K27R 1.5 3 106
K33R 1.7 3 106
K27R-K33R 1.9 3 106
a
of immunoprecipitations of 35S pulse-chase-labeled Gag proteins are
er untreated or treated with proteasome inhibitors (10 mM z-LLL and
ated at left while the inhibitor treatment and the lysate presented are
nd 8 h after the pulse) are presented from left to right for each image.
age analysis, are presented as the percentage of Gag released from
nside and outside the cell over time. (C) Release of Gag that is not
he percentage of Gag remaining in the supernatant after centrifugationGE gels
ere eith
re indic
, 2, 4, a
d by im
both iBlue cell-forming units per milliliter as determined by HCLZ assay.
b Sheared salmon sperm DNA (negative control).
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116 OTT ET AL.produce WT/PR2 and K27R-K33R/PR2. Virions produced
by transfection were separated by HPLC and the frac-
tions that contained Pr55Gag were examined for ubiquiti-
nation. The amount of K27R-K33R/PR2 virions examined
as approximately three times the amount of WT/PR2
virions, as measured by relative A206 absorbance. The
ubiquitin immunoblot of fraction 42 detected a 63-kDa
protein that, after the same blot was stripped and re-
probed, also reacted with p24CA antiserum (Fig. 6). The
63-kDa species was also present in a p6Gag immunoblot
data not shown). These data confirm that the p6Gag
sequences in Pr55Gag itself can be monoubiquitinated. In
ontrast, immunoblots of the protease-deficient K27R-
33R virions did not show this 63-kDa species, demon-
trating that the lysines in p6Gag are the principle mono-
ubiquitinated sites in Gag within virions (Fig. 6). However,
there was a faint, yet thick, band that was detectable in
the ubiquitin blot, in the same region in which the Pr55Gag
band appeared in the p24CA blot. This is most likely the
esult of a faint, nonspecific binding of the ubiquitin
onoclonal to large amounts of Gag, as previously re-
orted (Ott et al., 1998). This artifact is not present in the
T/PR2 blot, as there is less Pr55Gag in that lane.
ree ubiquitin in K27R-K33R
In addition to the ubiquitin–p6Gag conjugate, free ubiq-
uitin was previously found inside the virion (Ott et al.,
1998). Since ubiquitin conjugates can be rapidly removed
by one of many isopeptidases inside the cell (D’Andrea
and Pellman, 1998; Hochstrasser, 1996), ubiquitin could
FIG. 5. Replication kinetics of K27R-K33R. A representative graph of
a viral replication assay with H9 cells, as measured by an increase in
reverse transcriptase activity released into the culture media, is pre-
sented over time. Symbols for the various virus samples are presented
on the figure. The (-) line denotes data from cells that were not treated,
while the line labeled sssDNA indicates the data from cells infected
with sssDNA transfection supernatants. Two independent clones of
K27R-K33R (1 and 2) are presented.be initially brought into the assembling virion as a ubiq-
uitin–Gag complex that is subsequently removed to pro-duce free ubiquitin within the virion after budding. To
examine whether the lysines in p6Gag are responsible for
ubiquitin incorporation, K27R-K33R mutant virions were
examined for the presence of free ubiquitin. One com-
plication to the analysis of cellular proteins inside the
virion is the potential presence of contaminating pro-
teins, including ubiquitin, that are often found adhering to
the viral surface or in microvesicles (Bess et al., 1997;
Gluschankof et al., 1997; Ott et al., 2000). We developed
technique using a nonspecific protease, subtilisin, that
emoves proteins from outside the virion so that those
nside can be studied. This procedure removes more
han 95% of the microvesicle-associated proteins from a
reparation as well as the proteins on the virion surface
Ott et al., 1995, 1996, 2000).
To examine K27R-K33R mutant virions for the pres-
nce of free ubiquitin, viral preparations from both mu-
ant and wild-type transfections were first digested with
ubtilisin, and then the virions were reisolated by su-
rose density centrifugation and examined for ubiquitin
y immunoblot analysis. Comparison of the 5-kDa ubiq-
itin signal in the protease-treated versus mock-treated
amples clearly demonstrated that a considerable
mount of the ubiquitin in the treated samples was re-
oved (Fig. 7) and thus was outside the virion. However,
he remaining signal in the treated K27R-K33R mutant
nd wild-type lanes showed that both samples contained
clearly detectable and similar amount of ubiquitin,
FIG. 6. Analysis of protease-deficient virions. Immunoblots of HPLC
fractions containing Pr55Gag from virus samples are presented. The
virus sample subjected to HPLC and the antiserum or antibody used in
the blot are identified above each blot. Molecular weights, calculated
by relative mobility with a standard, are indicated at left and our protein
assignments are presented at right. The positions of the higher molec-
ular weight standards are presented as arrows at left.
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117UBIQUITINATION OF HIV-1 AND MuLV Gagindicating it was inside the virion. Interestingly, the blot
had a diffuse region of anti-ubiquitin reactivity (migrating
at a relative position above the 45-kDa protein standard)
in both the treated and untreated samples. It is important
to note that the ubiquitin antibody used for these studies
can detect both mono- and polyubiquitin forms. This
suggests that polyubiquitinated proteins are incorpo-
rated inside the virion. Stripping and reprobing the im-
munoblot with p24CA antiserum produced equivalent in-
tensity bands for the protease and mock-digested sam-
ples, indicating that p24CA and proteins on the interior of
the virus were protected from subtilisin by the viral mem-
brane as previously demonstrated (Ott et al., 1995, 1996,
2000) (Fig. 7). However, the untreated samples for both
mutant and wild-type virions also produced a less in-
tense Pr55Gag band and a faint lower band (probably a
Gag-processing intermediate) that were absent in the
treated samples and thus were removed by protease
treatment, indicating that they were not within intact
FIG. 7. Subtilisin treatment of virions. Immunoblots of mock-treated
(labeled “2”) and protease-treated (labeled “1”) virions are presented
with each sample labeled above its respective lane, and the antiserum
or antibody used is indicated above each blot. Molecular weights,
calculated by relative mobility with a standard, are indicated at left and
our protein assignments are presented at right. The positions of the
higher molecular weight standards are presented as arrows at right.particles. Since readily detectable amounts of ubiquitin
were incorporated by both the K27R-K33R mutant andthe wild-type virus, our results show that the incorpora-
tion of free ubiquitin found in the virion does not require
the lysines in p6Gag.
Ubiquitination of MuLV Gag
Our previous biochemical analysis found that the
p12Gag protein of MuLV, the protein that also contains the
uLV L domain, is monoubiquitinated on a lysine at
esidue 10, while the other lysine in p12Gag, K12, does not
ppear to be modified (Ott et al., 1998). To examine the
importance of the monoubiquitination of MuLV Gag, we
introduced mutations into p12Gag. Previous mutagenesis
tudies on other proteins showed that mutation of a
ysine often results in the ubiquitination of an adjacent
ysine in the target protein (Chau et al., 1989; Hou et al.,
1994; Treier et al., 1994). Given these results and our
results with HIV-1 presented above, both lysines were
mutated to arginine to produce a mutant, K10R-K12R, that
could not be ubiquitinated on p12Gag. The mutations were
introduced into an infectious molecular clone of Moloney
MuLV (Gorelick et al., 1988) (Fig. 1), and mutant virions,
produced by transfection of 293T cells, were analyzed
and compared to those of the wild-type. Similar reverse
transcriptase levels were produced by two clones of the
mutant and wild-type constructs (Table 2). The titer of the
mutants, as measured by the S1L2 focus-forming assay
which measures the titer of replicating MuLV on a focus-
orming indicator line), was essentially the same as that
f wild-type, showing that ubiquitination of p12Gag is not
required for infectivity.
Immunoblotting with p30CA antiserum of wild-type and
he mutant virions produced by transfection showed that
imilar amounts of p30CA were present in both samples,
indicating that nearly equal amounts of mutant and wild-
type virions were produced (Fig. 8). The presence of
p30CA suggests that Pr65Gag was processed normally in
the mutant. Ubiquitin immunoblots of the MuLV samples
were not sensitive enough to detect the ubiquitin-p12Gag
conjugate, likely because of the limited amounts of virus
produced by transfection. Similar to our results with
HIV-1, these data show that the absence of MuLV p12Gag
ubiquitination produced no significant effect on viral as-
sembly and budding.
TABLE 2
Infectivity of MuLV Mutants
Virus Reverse transcriptase Titera
sssDNAb 1.0 3 103 ,1
Wild-type 5.1 3 105 3 3 105
K10R–K12R (1)c 5.8 3 105 6 3 105
K10R–K12R (2)c 6.2 3 105 2 3 105
a Focus forming units per milliliter as determined by S1L2 assay.
b Sheared salmon sperm DNA (negative control).
c Independently isolated DNA clones.
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Our data show that the ubiquitination of HIV-1 p6Gag or
uLV p12Gag is not required for viral replication: infection,
assembly, and budding appear to occur normally in the
absence of this modification. For HIV-1, our data also
showed that either one or two ubiquitin molecules can
be conjugated to lysine 27 or lysine 33. Whereas we
detect both mono- and diubiquitinated forms, the data
presented here and in our previous study (Ott et al., 1998)
ndicate that the majority of the modified p6Gag is conju-
ated to a single ubiquitin. However, our results cannot
stablish which of the two lysines is normally modified in
ild-type p6Gag; it is possible that both can be alternately
odified, though this is not the case for MuLV p12Gag (Ott
t al., 1998). Others have found that ubiquitination can be
romiscuous: mutation of a lysine that is normally mod-
fied often causes a nearby lysine to be modified (Chau
t al., 1989; Hou et al., 1994; Treier et al., 1994). Unfortu-
nately, the small amounts of conjugate present (approx-
imately 2% of Gag) and the considerable distance of the
lysines from the N-terminus of the protein preclude the
direct identification of the normally modified lysine in
p6Gag by protein sequence analysis.
Recently, Yuan et al. (1999) produced a series of mu-
tants that placed a block of five alanine substitutions in
different regions throughout MuLV p12Gag. The mutant
covering the two lysines, alanines at positions 10–14,
was not infectious, even though assembly, viral entry,
and reverse transcription occurred normally. Our results
for MuLV appear to rule out the ubiquitination of p12Gag
as a cause for this effect.
Our data showed that p6Gag can be ubiquitinated as a
art of the Pr55Gag polyprotein. This suggests that ubiq-
itin is added to the p6Gag region of the assembling Gag
precursor, which is then processed into p6Gag by the viral
FIG. 8. Immunoblot of MuLV virions. A p30CA immunoblot of samples
from wild-type virus and two independently derived K10R-K12R mutant
(clone 1 and 2) viruses. The analysis of 10% of each preparation,
produced by transfection (approximately 60,000 cpm of reverse tran-
scriptase activity), is presented. Each sample is labeled above its
respective lane with molecular weights, calculated by relative mobility
with a standard, indicated at left and our protein assignment presented
at right.protease. The absence of detectable monoubiquitination
of K27R-K33R Gag suggests that the wild-type Pr55Gag
t
qincorporated into virions is primarily monoubiquitinated
at these two lysines.
Recently, we found that proteasome inhibitor treatment
of HIV-1-producing cells decreases the budding and pro-
cessing of Gag, producing an effect similar to that of an
L-domain mutant (Schubert et al., in press). In addition to
the effects on virus release and processing, we found
that proteasome inhibitor treatment eliminated the
monoubiquitination of p6Gag. The experiments presented
here show that the ubiquitination of p6Gag is not required
or these inhibitors’ effect on viral budding and process-
ng. Therefore, the loss of p6Gag ubiquitination after treat-
ment is likely the consequence of the interruption of the
ubiquitination system by the proteasome inhibitors.
It was previously shown that proteasome inhibitor
treatment of target cells increased the efficiency of in-
fection, suggesting that some of the infecting particles
are degraded by the proteasome after cell entry
(Schwartz et al., 1998). Although many roles of ubiquiti-
nation are unclear, monoubiquitination is stable, not in-
volved in proteasomal degradation, and often appears to
function in regulation of cell surface proteins (Hicke,
1999; Thrower et al., 2000). Our pulse-chase experiments
did not detect a difference in the intracellular stability of
wild-type versus the K27R-K33R mutant Gag, suggesting
that the monoubiquitinated form is not significantly de-
graded. Therefore, the amount of monoubiquitinated Gag
present in the virions and the ability of the K27R-K33R
mutant to efficiently replicate make it unlikely that the
effect described by Schwartz et al. (1998) is mediated by
the ubiquitin–p6Gag complexes within the virion.
Analysis of the proteins inside the K27R-K33R mutant
showed that incorporation of free ubiquitin into the virion
was independent of the ubiquitination of p6Gag, excluding
the possibility that ubiquitin is brought into the virion as
a conjugate with p6Gag, which is subsequently removed
fter budding. Free ubiquitin was previously found in
everal viruses: HIV-1, SIV, MuLV, and avian leukosis
irus (ALV) (Ott et al., 1998; Putterman et al., 1990). Al-
hough Gag–ubiquitin complexes were found in HIV, SIV,
nd MuLV, they were not detected in ALV using relatively
ensitive methods, showing that ubiquitin can be incor-
orated without detectable ubiquitination of Gag inside
he virion.
Ubiquitin is added to proteins by a protein–protein
nteraction between the targeted protein and a ubiquitin
igase activity that is presumably part of a multiprotein
omplex (Ciechanover, 1998; Finley and Chau, 1991; Her-
hko and Ciechanover, 1998; Hochstrasser, 1996; Laney
nd Hochstrasser, 1999). Unlike some other posttransla-
ional modifications (e.g., glycosylation), there is no ubiq-
itination signal per se surrounding the lysine to be
odified; rather the specificity of ubiquitination is
chieved by protein interactions that can be some dis-
ance away from the modified site in the primary se-
uence. Therefore, target binding is separate from con-
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119UBIQUITINATION OF HIV-1 AND MuLV Gagjugation, explaining the lack of specificity for a particular
lysine. Although how they function is not yet known, L
domains, a PTAP sequence for HIV-1 (Huang et al., 1995),
and a PPPY for MuLV (Yuan et al., 2000) probably interact
with cellular proteins to effect viral budding (Garnier et
al., 1996; Puffer et al., 1998). Ubiquitinating enzymes are
often components in cellular complexes inside the cell
that are involved in various cellular processes (Ciech-
anover, 1998). Considering our data, the ubiquitination of
p6Gag does not appear to play a direct role in virus
ssembly and budding. However, this modification might
e a consequence of a cellular-ubiquitinating complex
nteracting with the assembling Gag, rather than an
vent required for viral function. Ubiquitination as a by-
roduct of protein–protein interactions was recently de-
cribed for the internalization of the mammalian growth
ormone receptor. In this case, a sequence is necessary
or internalization and ubiquitination of the receptor, but
he ubiquitination of the protein itself is not required for
his function (Govers et al., 1999).
Whereas our data show that ubiquitination of either
6Gag or p12Gag is not required for replication in vitro, the
presence of ubiquitin–Gag complexes at least shows
that a small portion of Gag interacts with a ubiquitinating
activity. Since lysines 27 and 33 are highly conserved in
the p6Gag of nearly all HIV-1 isolates (Myers et al., 1995),
they and possibly their ubiquitination might be important
for an in vivo function that is not necessary in vitro. Our
esults might assist in the discovery of the host proteins
nd complexes that interact with HIV-1 in the late assem-
ly and budding process.
MATERIALS AND METHODS
NA mutagenesis
The pNL4-3 infectious molecular clone of HIV-1 (Ada-
hi et al., 1987) (GenBank Accession No. m19921) was
ltered by site-directed mutagenesis using the PCR-
ased overlap extension procedure (Horton et al., 1990).
riefly, ApaI–BclI fragments containing the desired mu-
ations were cloned into pNL4-3 as previously described
Ott et al., 1999). Mutations introduced into p6Gag by this
method are as follows: K27R, nt 2212, A-G; K33R, nt 2230,
A-G; and K27R-K33R, nt 2212, A-G and nt 2230, A-G. The
protease-deficient mutant PRR57G was produced in
pNL4-3 by a C-G change at nt 2421. After construction,
the PCR-amplified regions of the various mutants were
DNA sequenced to confirm the mutation and the integrity
of the sequences exposed to the mutagenesis process.
Cell culture methods
The 293T transformed human kidney, HeLa, and
HeLa–CD4–LTR-lacz (HCLZ) (gift of David Waters, AIDS
Vaccine Program) cell lines were cultured in Dulbecco’s
modified Eagle’s medium; H9 T-cell leukemia cells werecultured in RPMI 1640; and the D56 S1L2 cells were
cultured in McCoy’s medium. All media were supple-
mented with 10% v/v fetal bovine serum, 2 mM L-glu-
tamine, and 100 U/ml penicillin and 100 mg/ml strepto-
ycin. All cell culture products were obtained from Life
echnologies (Gaithersburg, MD). Transient transfec-
ions of 293T cells were carried out using a calcium
hosphate mammalian cell transfection kit (5 Prime3 3
Prime, Boulder, CO) according to the manufacturer’s rec-
ommendation. Virion production was measured by re-
verse transcriptase assay on cell culture supernatants
as previously described for HIV-1 (Mg21) (Gorelick et al.,
990) and MuLV (Mn21) (Gorelick et al., 1996). The HIV-1
infection assays (HCLZ) were carried out as previously
described (Gorelick et al., 1990). Virus replication assays
were carried out as follows: 0.1% of the virus from a
transfection (approximately 6000 cpm of reverse tran-
scriptase activity) was used to infect 1 3 106 H9 cells in
24-well plate (Costar, Cambridge, MA) and clarified
amples were taken routinely and monitored for reverse
ranscriptase activity. All HIV-1 infections were carried
ut in the presence of 2 mg/ml Polybrene. The MuLV
S1L2 focus assay with a 5 mg/ml dextran sulfate (Sigma,
t. Louis, MO) pretreatment of the cells was carried out
s previously described (Bassin et al., 1971) .
rotein analysis
Virions were isolated by centrifugation through a 20%
ucrose pad in a SW28Ti rotor (Beckman-Coulter, Fuller-
on, CA) at 25,000 rpm at 4°C for 1 h. Subtilisin treatment
f virions was carried out as previously described (Ott et
l., 1995). Immunoblot analysis on equal amounts of
irions, as measured by reverse transcriptase activity
;6 3 106 cpm), was performed as previously described,
using peroxidase-conjugated secondary antibodies with
chemiluminescence development using either ECL (Am-
ersham Life Science, Arlington Heights, IL) or the Super
Signal (Pierce Chemical, Rockford, IL) reagents (Hender-
son et al., 1988). Rabbit antiserum against p6Gag, p30CA,
nd p10PR and goat antiserum against p24CA were ob-
tained from the AIDS Vaccine Program. Monoclonal an-
tibodies against ubiquitin and reverse transcriptase were
obtained from Chemicon (Temecula, CA) or PanVera
(2C5; Madison, WI) and NEN Life Science (Boston, MA).
Microscale high-pressure liquid chromatography was
performed as previously described (Ott et al., 1999).
Pulse-chase analysis
Radiolabeling and immunoprecipitation were per-
formed according to a previously described protocol
(Schubert et al., 1998). Briefly, transfected HeLa cells
were starved for 45 min in methionine-free RPMI, labeled
with [35S]methionine for 30 min, and then washed and
incubated in complete media (chase). Culture superna-
tants and cells were sampled at varying times and the
BB
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120 OTT ET AL.samples were concentrated and lysed. Immunoprecipi-
tations were carried out as previously described, using
g-globulin from pooled plasma of healthy HIV-1 donors
(NIH AIDS Research and Reference Reagent Program,
Catalog No. 192). Precipitates were analyzed by SDS–
PAGE, visualized by fluorography, and quantitated by
image analysis (Molecular Dynamics, Sunnyvale, CA).
For proteasome inhibitor pulse-chase experiments, 10
mM z-LLL and 10 mM lactacystin (Calbiochem, San Di-
ego, CA) were added 30 min prior to labeling and main-
tained throughout the chase period.
ACKNOWLEDGMENTS
We thank Robert Gorelick for critical reading of the manuscript. This
project was funded, in part, with federal funds from the National Cancer
Institute, National Institutes of Health, under Contract NO1-CO-56000.
U.S. was supported by Grant Schu11/2-1 and a Heisenberg grant from
the Deutsche Forschungsgemeinschaft. The content of this publication
does not necessarily reflect the views or policies of the Department of
Health and Human Services, nor does mention of trade names, com-
mercial products, or organization imply endorsement by the U.S. Gov-
ernment.
REFERENCES
Adachi, A., Koenig, S., Gendelman, H. E., Daugherty, D., Gattoni-Celli, S.,
Fauci, A. S., and Martin, M. A. (1987). Productive, persistent infection
of human colorectal cell lines with human immunodeficiency virus.
J. Virol. 61, 209–213.
assin, R. H., Tuttle, N., and Fischinger, P. J. (1971). Rapid cell culture
assay technique for murine leukaemia viruses. Nature 229, 564–566.
ess, J. W., Jr., Gorelick, R. J., Bosche, W. J., Henderson, L. E., and Arthur,
L. O. (1997). Microvesicles are a source of contaminating cellular
proteins found in purified HIV-1 preparations. Virology 230, 134–144.
hau, V., Tobias, J. W., Bachmair, A., Marriott, D., Ecker, D. J., Gonda,
D. K., and Varshavsky, A. (1989). A multiubiquitin chain is confined to
specific lysine in a targeted short-lived protein. Nature 243, 1576–
1583.
Ciechanover, A. (1998). The ubiquitin-proteasome pathway: On protein
death and cell life. EMBO J. 17, 7151–7160.
D’Andrea, A., and Pellman, D. (1998). Deubiquitinating enzymes: A new
class of biological regulators. Crit. Rev. Biochem. Mol. Biol. 33,
337–352.
Dettenhofer, M., and Yu, X. F. (1999). Proline residues in human immu-
nodeficiency virus type 1 p6(Gag) exert a cell type-dependent effect
on viral replication and virion incorporation of Pol proteins. J. Virol.
73, 4696–4704.
inley, D., and Chau, V. (1991). Ubiquitination. Annu. Rev. Cell Biol. 7,
25–69.
arnier, L., Wills, J. W., Verderame, M. F., and Sudol, M. (1996). WW
domains and retrovirus budding. Nature 381, 744–745.
luschankof, P., Mondor, I., Gelderblom, H. R., and Sattentau, Q. J.
(1997). Cell membrane vesicles are a major contaminant of gradient-
enriched human immunodeficiency virus type-1 preparations. Virol-
ogy 230, 125–133.
Gorelick, R. J., Chabot, D. J., Ott, D. E., Gagliardi, T. D., Rein, A.,
Henderson, L. E., and Arthur, L. O. (1996). Genetic analysis of the zinc
finger in the Moloney murine leukemia virus nucleocapsid: Replace-
ment of zinc-binding residues with other zinc-binding residues yields
noninfectious particles containing genomic RNA. J. Virol. 70, 2593–
2597.Gorelick, R. J., Henderson, L. E., Hanser, J. P., and Rein, A. (1988). Point
mutants of Moloney murine leukemia virus that fail to package viralRNA: Evidence for specific RNA recognition by a “zinc finger-like”
protein sequence. Proc. Natl. Acad. Sci. USA 85, 8420–8424.
Gorelick, R. J., Nigida, S. M., Bess, J. W., Jr., Henderson, L. E., Arthur,
L. O., and Rein, A. (1990). Noninfectious human immunodeficiency
virus type 1 mutants deficient in genomic RNA. J. Virol. 64, 3207–3211.
Gottlinger, H. G., Dorfman, T., Sodroski, J. G., and Haseltine, W. A. (1991).
Effect of mutations affecting the p6 gag protein on human immuno-
deficiency virus particle release. Proc. Natl. Acad. Sci. USA 88,
3195–3199.
Govers, R., Ten Broeke, T., Van Kerkhof, P., Schwartz, A. L., and Strous,
G. J. (1999). Identification of a novel ubiquitin conjugation motif,
required for ligand-induced internalization of the growth hormone
receptor. EMBO J. 18, 28–36.
Henderson, L. E., Sowder II, R. C., Smythers, G., and Oroszlan, S. (1988).
Chemical and immunological characterizations of equine infectious
anemia virus gag-encoded proteins. J. Virol. 61, 2587–2595.
Hershko, A., and Ciechanover, A. (1998). The ubiquitin system. Annu.
Rev. Biochem. 67, 425–479.
Hicke, L. (1999). Gettin’ down with ubiquitin: Turning off cell-surface
receptors, transporters and channels. Trends Cell Biol. 9, 107–112.
Hochstrasser, M. (1996). Ubiquitin-dependent protein degradation.
Annu. Rev. Genet. 30, 405–439.
Horton, R. M., Cai, Z., Ho, S. N., and Pease, L. R. (1990). Gene splicing
by overlap extension: Tailor-made genes using polymerase chain
reaction. BioTechniques 8, 528–535.
Hou, D., Cenciarelli, C., Jensen, J. P., Nguygen, H. B., and Weissman,
A. M. (1994). Activation-dependent ubiquitination of a T cell antigen
receptor subunit on multiple intracellular lysines. J. Biol. Chem. 269,
14244–14247.
Huang, M., Orenstein, J. M., Martin, M. A., and Freed, E. O. (1995). p6gag
is required for particle production from full-length human immuno-
deficiency virus type 1 molecular clones expressing protease. J. Virol.
69, 6810–6818.
Kimpton, J., and Emerman, M. (1992). Detection of replication-compe-
tent and pseudotyped human immunodeficiency virus with a sensi-
tive cell line on the basis of activation of an integrated beta-galac-
tosidase gene. J. Virol. 66, 2232–2239.
Kra¨usslich, H. G., and Welker, R. (1996). Intracellular transport of retro-
viral capsid components. Curr. Top. Microbiol. Immunol. 214, 25–63.
Laney, J. D., and Hochstrasser, M. (1999). Substrate targeting in the
ubiquitin system. Cell 97, 427–430.
Lee, D. H., and Goldberg, A. L. (1998). Proteasome inhibitors: Valuable
new tools for cell biologists. Trends Cell Biol. 8, 397–403.
Myers, G., Korber, B., Hahn, B. H., Jeang, K.-T., Mellors, J. W., Mccutchan,
F. E., Henderson, L. E., and Pavlakis, G. N. (1995). Human retroviruses
and AIDS 1995: A compilation and analysis of nucleic acid and amino
acid sequences. Los Alamos National Laboratory, Los Alamos, NM.
Ott, D. E., Chertova, E. N., Busch, L. K., Coren, L. V., Gagliardi, T. D., and
Johnson, D. G. (1999). Mutational analysis of the hydrophobic tail of
the human immunodeficiency virus type 1 p6(Gag) protein produces
a mutant that fails to package its envelope protein. J. Virol. 73, 19–28.
Ott, D. E., Coren, L. V., Copeland, T. D., Kane, B. P., Johnson, D. G.,
Sowder II, R. C., Yoshinaka, Y., Oroszlan, S., Arthur, L. O., and Hen-
derson, L. E. (1998). Ubiquitin is covalently attached to the p6Gag
proteins of human immunodeficiency virus type-1 and simian immu-
nodeficiency virus and the p12Gag protein of Moloney murine leu-
kemia virus. J. Virol. 72, 2962–2968.
Ott, D. E., Coren, L. V., Johnson, D. G., Kane, B. P., Sowder II, R. C., Kim,
Y. D., Fisher, R. J., Zhou, X. Z., Lu, K. P., and Henderson, L. E. (2000).
Actin-binding cellular proteins inside human immunodeficiency virus
type 1. Virology 266, 42–51.
Ott, D. E., Coren, L. V., Johnson, D. G., Sowder II, R. C., Arthur, L. O., and
Henderson, L. E. (1995). Analysis and localization of cyclophilin A
found in the virions of human immunodeficiency virus type 1 MN
strain. AIDS Res. Hum. Retroviruses 11, 1003–1006.Ott, D. E., Coren, L. V., Kane, B. P., Busch, L. K., Johnson, D. J., Sowder
II, R. C., Chertova, E. N., Arthur, L. O., and Henderson, L. E. (1996).
PP
S
S
S
T
T
V
Y
Y
121UBIQUITINATION OF HIV-1 AND MuLV GagCytoskeletal proteins inside human immunodeficiency virus type 1
virions. J. Virol. 70, 7734–7743.
Parent, L. J., Bennett, R. P., Craven, R. C., Nelle, T. D., Krishna, N. K.,
Bowzard, J. B., Wilson, C. B., Puffer, B. A., Montelaro, R. C., and Wills,
J. W. (1995). Positionally independent and exchangeable late budding
functions of the Rous sarcoma virus and human immunodeficiency
virus Gag proteins. J. Virol. 69, 5455–5460.
Puffer, B. A., Parent, L. J., Wills, J. W., and Montelaro, R. C. (1997). Equine
infectious anemia virus utilizes a YXXL motif within the late assembly
domain of the Gag p9 protein. J. Virol. 71, 6541–6546.
uffer, B. A., Watkins, S. C., and Montelaro, R. C. (1998). Equine infec-
tious anemia virus gag polyprotein late domain specifically recruits
cellular AP-2 adapter protein complexes during virion assembly.
J. Virol. 72, 10218–10221.
utterman, D., Pepinsky, R. B., and Vogt, V. M. (1990). Ubiquitin in avian
leukosis virus particles. Virology 176, 633–637.
cheffner, M., Smith, S., and Jentsch, S. (1998). The ubiquitin-conjuga-
tion system. In “Ubiquitin and the Biology of the Cell” (J.-M. Peters,
J. R. Harris, and D. Finley, Eds.), pp. 65–98. Plenum Press, New York.
chubert, U., Anton, L. C., Bacik, I., Cox, J. H., Bour, S., Bennink, J. R.,
Orlowski, M., Strebel, K., and Yewdell, J. W. (1998). CD4 glycoprotein
degradation induced by human immunodeficiency virus type 1 Vpu
protein requires the function of proteasomes and the ubiquitin-
conjugating pathway. J. Virol. 72, 2280–2288.
chubert, U., Anton, L. C., Gibbs, A., Norbury, C. C., Yewdell, J. W., and
Bennink, J. R. (2000). Rapid degradation of a large fraction of newly
synthesized proteins by proteasomes. Nature 404, 770–774.Schubert, U., Ott, D. E., Chertova, E. N., Welker, R., Tessmer, U., Princi-
otta, M., Bennick, J. R., Krausslich, H.-G., and Yewdell, J. W. Protea-some inhibition interferes with Gag polyprotein processing, release,
and maturation of human immunodeficiency viruses. Proc. Natl.
Acad. Sci. USA, in press.
Schwartz, O., Marechal, V., Friguet, B., Arenzana-Seisdedos, F., and
Heard, J. M. (1998). Antiviral activity of the proteasome on incoming
human immunodeficiency virus type 1. J. Virol. 72, 3845–3850.
Shih, S. C., Sloper-Mould, K. E., and Hicke, L. (2000). Monoubiquitin
carries a novel internalization signal that is appended to activated
receptors. EMBO J. 19, 187–198.
Swanstrom, R., and Wills, J. (1997). Synthesis, assembly, and process-
ing of viral proteins. In “Retroviruses” (J. Coffin, S. Hughes, and H.
Varmus, Eds.), pp. 263–334. Cold Spring Harbor Laboratory Press,
Plainview, NY.
hrower, J. S., Hoffman, L., Rechsteiner, M., and Pickart, C. M. (2000).
Recognition of the polyubiquitin proteolytic signal. EMBO J. 19, 94–
102.
reier, M., Staszewski, L. M., and Bohmann, D. (1994). Ubiquitin-depen-
dent c-Jun degradation in vivo is mediated by the delta domain. Cell
78, 787–798.
ogt, V. (1997). Retroviral virions and genomes. In “Retroviruses” (J.
Coffin, S. Hughes, and H. Varmus, Eds.), pp. 27–70. Cold Spring
Harbor Laboratory Press, Plainview, NY.
uan, B., Campbell, S., Bacharach, E., Rein, A., and Goff, S. P. (2000).
Infectivity of Moloney murine leukemia virus defective in late assem-
bly. J. Virol. 74, 7250–7260.
uan, B., Li, X., and Goff, S. P. (1999). Mutations altering the Moloney
murine leukemia virus p12 Gag protein affect virion production and
early events of the virus life cycle. EMBO J. 18, 4700–4710.
